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initiated on an antidepressant or antihypertensive medicine. Rather than providing a 
sample (or starter pack), the GP prescribed a reduced quantity of the chosen medica-
tion for dispensing by a community pharmacy. Action research cycles allowed local 
changes to the initial protocol by study practitioners. Prescription dispensing histories 
were obtained to track time between starter pack and full quantity dispensing. GP 
follow-up appointments were tracked via practice appointment systems. Practitioner 
and patient satisfaction surveys were conducted. RESULTS: Two primary care general 
practices with a pharmacy nearby participated. Thirty-one patients received 32 starter 
prescriptions. The average age was 43.9 years (SD 16.7, range 23–80) with 44% being 
male. Twenty-nine starter prescriptions were dispensed with 17 tracked to full pre-
scription dispensing. Thirteen (45%) prescriptions were for antihypertensives. Study 
prescriptions were always dispensed as a generic brand, whenever one was available. 
This occurred for 11 (69%) of antidepressants and 3 (23%) of antihypertensives. 
Twenty-eight patients (87%) made a follow-up appointment, however 11 were outside 
the time window deemed appropriate for completion of the starter pack. Survey 
responses showed all patients were satisﬁed with information provided by their GP 
and pharmacist, and agreed starter packs facilitate trial of a new medicine (new to 
the patient, not necessarily new to the market). Patients, GPs and pharmacists 
approved of the pilot protocol. CONCLUSIONS: Community pharmacist involve-
ment in dispensing starter packs was practical and acceptable to practitioners and 
patients. A similar model could be tailored for other jurisdictions based on local 
requirements to avoid adverse consequences associated with current systems of pre-
scriber-distributed free prescription medicine samples.
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OBJECTIVES: To perform a comparative assessment of the medical beneﬁt of ASA           
for secondary prevention of cardiovascular events in patients with peripheral arterial 
disease (PAD) using existing published data. METHODS: In a systematic literature    
search up to January 2009 according to the methodological guidance documents of 
the IQWiG relevant publications of RCTs and systematic reviews were detected. Study 
characteristics and results were extracted and presented in evidence tables. RESULTS: 
Overall 16 studies (18 publications) were included in the analyses. The methodological 
approaches of the studies were heterogeneous and especially the older studies have 
some major methodological restrictions. There was no statistically signiﬁcant differ-
ence of ASA compared to all other alternatives incl. placebo with regard to overall 
mortality, risk of myocardial infarction or stroke. A statistically signiﬁcant disadvan-
tage compared to clopidogrel was shown for vascular mortality and a combined end-
point of vascular mortality, myocardial infarction and stroke. Using this combined 
endpoint a signiﬁcant advantage of ASS compared to placebo was shown. With regard 
to adverse events ASA had a tendency to higher discontinuation rates and a higher 
incidence of gastrointestinal problems. CONCLUSIONS: Overall the analyses using    
the IQWiG’s approach for the assessment of medical beneﬁts showed no advantage 
of a monotherapy with ASA compared to other alternatives incl. placebo for secondary 
prevention of cardiovascular events in patients with PAD. The currently available 
published data do not justify a general recommendation of ASA in PAD patients with 
regard to cardiovascular endpoints. The analysis shows the need also to assess the 
beneﬁt of long time used pharmaceuticals to avoid a potential ritualized and inefﬁcient 
use. Furthermore the results are necessary in the IQWiG’s assessments of more innova-
tive technologies to have valid information of standard comparators, too.
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OBJECTIVES: Elevated low-density lipoprotein cholesterol (LDL-C) is the primary        
treatment target for patients at risk of coronary heart disease (CHD). Low high-density 
lipoprotein cholesterol (HDL-C) and elevated triglycerides (TG) are also risk factors 
for CHD, however often remain unaddressed. This cross-sectional study attempted to 
identify the extent of prevalence of low HDL-C and/or elevated TG combined with 
elevated LDL-C among patients treated with lipid modifying therapy (LMT) in 
Hungary. METHODS: Using 8,768 we identiﬁed patients who were at least 35 years           
of age treated with a LMT for at least 6 weeks and also had a complete lipid proﬁle 
within the past 6 weeks. Patients were considered to be at high CV risk if they had a 
history of CV disease, or type II diabetes or 10 year CHD risk q 20%. Current Euro-
pean Society of Cardiology guidelines were used to deﬁne lipid threshold levels. 
RESULTS: In a sample of 1,373 high CV risk patients treated with LMT, slightly over              
80% patients experienced q1 lipid abnormality. Among these, 64% had elevated 
LDL-C while approximately 37% had elevated LDL-C along with HDL-C and/or TG 
abnormality. Nearly 33% of treated high risk patient experiencing lipid abnormality 
had low HLD-C level and 56% experienced elevated TG problem. Approximately 
12% of the sample with any lipid abnormality had all 3 lipid abnormalities. CON-
CLUSIONS: In this cross-sectional study of Hungarian high CV risk patients treated           
primarily with statins, ~80% of all patients with at least one lipid abnormalities 
experienced elevated LDL-C. In addition, 45% of treated high CV risk patient still 
had TG or HDL (or both) lipid abnormalities who could potentially beneﬁt from other 
lipid-modifying therapies in addition to statins.
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OBJECTIVES: To assess the ﬁrst Japanese guideline for the management of stroke 
developed in 2004 (Int J Stroke 2007; 2: 133–135) by a formal method. METHODS: 
This guideline was critically appraised using three instruments of AGREE, COGS and 
Shaneyfelt by independent reviewers from the developers. They consisted of 22 stroke 
physicians, 8 general physicians, and 11 nurses. Best evaluation corresponds to 100% 
of response rate. RESULTS: A response rate was ranging from 66 to 91% with regard 
to each of many checklists . There was no distinction among the appraisal instruments. 
Among those, the dimensions of scope/purpose (89%), rigor of development (83%), 
and clarity/presentation (76%) were highly approved in integrity of the guideline, yet, 
relatively lower in editorial independence (71%), stakeholder involvement (70%), and 
applicability (69%). Nurses tended to provide a more faborable response. CONCLU-
SIONS: The Japanese guideline for the management of stroke was ﬁrst formally 
evaluated and turned out to be fairly acceptable.
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OBJECTIVES: According to JNC 7 guidelines, most hypertensive patients require 
multiple drugs—as individual agents or ﬁxed-dose combinations (FDCs)—to achieve 
blood pressure goals. They suggest that FDCs may be simplest, most convenient, and 
most cost-effective. However, usage patterns for FDCs are not fully known. Our 
objective was to explore prescription treatment patterns for monotherapy and com-
bination therapy for US adults with diagnosed hypertension. METHODS: Data were 
obtained from the 2007 US National Health and Wellness Survey (NHWS) quarters 
1–3. The NHWS is an annual, nationally representative, Internet-based survey of 
adults (q18 years). Respondents were asked about their hypertension and its treatment. 
Drugs reported were compared for monotherapy versus combinations (single agents 
and/or FDCs) and grouped by class: angiotensin II receptor blockers (ARBs), A- or B-
blockers, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) 
inhibitors, and diuretics including hydrochlorothiazide. RESULTS: Respondents 
 numbered 19,874. Of 16,495 (83%) who reported using prescription therapy, 215 
(1%) responded ambiguously, whereas 7705 (47%) received single-agent mono-
therapy: an ACE inhibitor (2828 [37%] of 7705), a B-blocker (1796 [23%]), or 
something else. The remaining 8575 (52% of 16,495) patients received combination 
therapies: two single agents with no FDC (3516 [41%] of 8575), three or more single 
agents with no FDC (2285 [27%]), an FDC alone (1517 [18%]), an FDC plus one 
agent (744 [9%]), an FDC plus two single agents (432 [5%]), or other (81 [1%]). 
Common FDC-only therapies were an ARB  hydrochlorothiazide (713 [47%] of 
1517 patients), and an ACE inhibitor  CCB (384 [25%]). CONCLUSIONS: More 
than half of the hypertensive respondents to the NHWS received at least two antihy-
pertensive agents, with the majority receiving multiple individual products instead of 
an FDC product. Understanding the factors contributing to this use proﬁle, such as 
cost, availability, convenience, and compliance, requires further exploration.
GASTROINTESTINAL DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: The advantage of selective inhibitors of cyclo-oxygenase-2 (COX-2 
NSAIDs) over other traditional non-selective NSAIDs (tNSAIDs) is that the risks of 
serious upper gastro-intestinal events are lower. This study aimed to assess the GI 
toxicity of tNSAIDs in comparison with COX-2 NSAIDs, comparing different epide-
miological designs. METHODS: Incident users of NSAIDs in Tayside, Scotland, 
UK were identiﬁed from January 1,2005 to 2007 from the population databases of 
the Health Informatics Centre. Confounders included age, gender, deprivation, co-
morbidity and prescribed ulcer healing drugs, and aspirin. Analysis of upper GI 
 hospitalisation utilised standard multiple regression analysis using Cox PH model; 
adjustment for propensity scores; and the Self Controlled Case Series (SCCS). 
RESULTS: From a total cohort of 68,736 users of NSAIDs, there were 1.5% 
(n  982) receiving a COX-2 NSAID, with Celecoxib having the highest proportion 
81.5% (n  800). Differences in baseline characteristics indicated that prescribing of 
COX-2 NSAIDs was more prevalent in the elderly, those who received aspirin, ulcer 
healing drugs and with a history of other GI hospitalisations. In the standard adjusted 
Cox PH model, those in receipt of COX-2 NSAIDs compared with other tNSAIDs 
had higher risk of upper GI events (HR  1.95, 95% CI 1.19, 3.17). After adjustment 
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for the propensity score this remained signiﬁcantly higher (HR  2.93, 95% CI 1.42, 
6.02) for those with concurrent aspirin, but was non-signiﬁcant in those with no 
concurrent aspirin (HR  1.48, 95% CI 0.76, 2.89). In contrast, in the SCCS the rela-
tive incidence (RI) of GI hospitalisation for COX-2 s vs tNSAIDs was 0.73 (0.604, 
0.998) in those with no concurrent ulcer healing drugs. CONCLUSIONS: Traditional 
cohort analysis methods only weakly adjust for confounding, especially confounding 
by indication. Case-only designs give results more akin to trials. Interpretation still 
requires care as each design makes crucial assumptions.
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OBJECTIVES: To estimate work productivity in Danish patients consulting primary 
care physicians with upper gastrointestinal (UGI) symptoms and the effect of acid-
suppressive therapy. METHODS: The RESPONSE study was a randomized, double-
blind, placebo-controlled primary care study focusing on proton pump inhibitor 
treatment of acid-related UGI symptoms. A secondary objective assessed improvement 
in productivity loss following 2 weeks of esomeprazole 40 mg once daily or placebo. 
Work productivity due to UGI symptoms was measured using the Work Productivity 
and Activity Impairment questionnaire speciﬁc for patients with UGI symptoms 
(WPAI : UGIS) and a Danish national average wage rate was applied to calculate the 
value of lost time. Treatment effect on work productivity loss was tested using 
Kolgomorov-Smirnov test. RESULTS: A total of 805 patients completed the study; 
423 patients reported being employed at baseline and were included in the analysis. 
The estimated total cost of average work productivity loss in the 7 days preceding 
contact with the physician was a316 (DKK 2355) per patient (95% conﬁdence interval 
[CI]: a277, a355). This was equivalent to 10.5 working hours/week, and increased 
with increasing severity of UGI symptoms at baseline. Of the total loss, absence from 
work contributed 2.2 hours/week (95% CI: 1.6, 2.8) and reduced productivity while 
at work (presenteeism) 8.3 hours/week (95% CI: 7.3, 9.3). After 2 weeks of treatment, 
the mean improvement in work productivity per week was signiﬁcantly higher for 
both absenteeism (1 hour vs. 0.1 hour, p  0.05) and presenteeism (5.3 hours vs. 4.3 
hours, p  0.05) in patients treated with esomeprazole vs placebo. The economic value 
of the incremental gain in productivity with esomeprazole vs. placebo was a45/week. 
CONCLUSIONS: The results indicate that acid-related UGI symptoms in Danish 
primary care patients represent a signiﬁcant economic burden in terms of lost produc-
tivity, which can be addressed with acid-suppressive therapy. Supported by AstraZen-
eca, Albertslund, Denmark.
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OBJECTIVES: To evaluate the efﬁcacy of iv PPIs in treating PUB. METHODS: 
 Randomised controlled trials (RCTs) identiﬁed in a Cochrane systematic review of 
CENTRAL, EMBASE and MEDLINE (1996 to November 2004) were supplemented 
with an update to December 2008 and then searched for RCTs with consistent pre-
randomization endoscopic haemostatic treatment (EHT) that compared any iv PPI 
with either placebo (including no treatment) or a histamine-2-receptor antagonist 
(H2RA). Data on overall mortality, rebleeding, emergency surgery and further EHT 
were extracted and re-analysed if not analysed by intention-to-treat. Summary effect 
estimates (Relative Risk, RR) were calculated by meta-analysis using a ﬁxed-effects 
model by the Mantel-Haenszel method. Quality of RCTs included in the meta-analysis 
was judged based on an assessment of the method of randomisation and concealment 
of allocation. Sensitivity analysis was conducted using the DerSimonian and Laird 
random-effects model. RESULTS: Of the 251 papers identiﬁed, 10 were suitable to 
provide data for analysis (4 PPI vs H2RA; 6 PPI vs placebo). When compared with 
either an H2RA or placebo, PPIs signiﬁcantly reduced rebleeding (RR 0.53; 95% 
Conﬁdence Interval [CI]: 0.41–0.68; p  0.00001), emergency surgery (RR 0.58; 
95%CI: 0.43–0.79; p  0.0004) and further EHT (RR 0.49; 95%CI: 0.38–0.64; 
p  0.00001). There was a non-signiﬁcant reduction in overall mortality (RR 0.85; 
95%CI: 0.59–1.21; p  0.35), which became signiﬁcant when a single outlier trial was 
excluded in a post-hoc analysis (RR 0.68; 95%CI: 0.46–0.99; p  0.05). The trial 
was excluded based on imbalanced patient allocation: substantially more patients with 
previous PUB were randomised to the placebo arm, and surviving a prior PUB is 
associated with increased likelihood of surviving a subsequent PUB. The sensitivity 
analysis using a random-effects model provided results consistent with the primary 
analysis. CONCLUSIONS: Intravenous PPIs have signiﬁcant beneﬁts over treatment 
with an H2RA or placebo for PUB, which may include a signiﬁcant reduction in overall 
mortality.
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OBJECTIVES: To determine the clinical effectiveness of three anti-TNF-A agents 
(inﬂiximab, adalimumab, etanercept) in refractory Crohn’s dissease (CD). METHODS: 
An electronic literature search was conducted to identify randomized controlled trials 
(RCT) and observational studies on CD and anti-TNF-a drugs that were published 
from 1996–2008 using Medline, EMBASE, PubMed, Wiley’s Cochrane Library, and 
Thomson’s BIOSIS Previews. Websites of professional associations were also searched. 
A random effect pooled analysis was performed when tw0 or more comparable stuides 
were identiﬁed. RESULTS: Of 2557 citations identiﬁed, the publications related to 13 
RCTs and 7 observational studies met the inclusion criteria. All included RCTs had 
a methodological quality score (Jadad scale) of 3 or more. Included effectiveness trials 
were largely placebo-controlled. Findings indicate that inﬂiximab is effective in induc-
tion and maintenance of clinical response and remission in patients with luminal or 
ﬁstulizing CD who are resistant or refractory to conventional therapy. Inﬂiximab also 
reduces the need for surgical resection and hospitalization in CD. Adalimumab was 
shown to be effective for inducing and maintaining clinical remission in CD patients 
with secondary non-response to inﬂiximab or who are naive to anti-TNF-A drugs. No 
statistically signiﬁcant difference was observed between adalimumab and placebo in 
terms of ﬁstula improvement or remission rates. However, a signiﬁcantly higher rate 
of ﬁstula remission was reported when adalimumab was used as maintenance therapy 
in one study. A majority of CD patients re-established reduced response after inﬂix-
imab or adalimumab dose escalation. The results of this review showed that CD 
patients with secondary non-response to inﬂiximab could beneﬁt from adalimumab 
therapy. CONCLUSIONS: Inﬂiximab and adalimumab have shown a consistent 
 superiority to placebo in induction and maintenance of clinical remission, as well 
as in reducing the rates of surgery and hospitalization in refractory CD. CD patients 
who begin to lose their response to anti-TNF-A treatment could beneﬁt from dose 
escalation.
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OBJECTIVES: Prucalopride is a selective 5-HT    4 agonist, effective for treatment of 
chronic constipation, as demonstrated in three pivotal phase III trials and a trial in 
elderly patients. The aim of this study was to explore if baseline patient characteristics 
could predict efﬁcacy of prucalopride after four weeks treatment. Two efﬁcacy 
outcome measures were considered: R1) response deﬁned as an increase from baseline 
of q1 point in patient-reported satisfaction with treatment; R2) response deﬁned as 
an average of q3 spontaneous complete bowel movements (SCBM) per week. 
METHODS: Data from four trials were combined (n  1256). Univariate associations 
of baseline characteristics with response were investigated. Stepwise logistic regression 
was used to build a predictive model and classiﬁcation trees analysis (CTA) models 
were constructed on data from a random selection of two-thirds of the patients. The        
predictive value of the constructed model was evaluated on the remaining one-third 
using ROC-curve analysis. RESULTS: Univariate associations identiﬁed 4 covariates 
strongly associated with R1 (satisfaction with treatment, abdominal pain, laxative use, 
rectal symptoms) and 10 with R2 (SCBM, CBM, SBM, BM, fewer BM than you like, 
satisfaction with BM frequency and regularity, abdominal symptoms, laxative use, 
frequency of BM in preceding six months). The ﬁnal stepwise logistic regression 
models contained the same baseline covariates, whereas the CTA-models contained 
fewer covariates, but had a comparable predictive value (67% positive predictive 
value, 80% sensitivity and 41% speciﬁcity for R1 and 44% positive predictive value, 
17% sensitivity and 91% speciﬁcity for R2). CONCLUSIONS: Self-reported satisfac-
tion with treatment, symptoms, and laxative use at baseline has meaningful predictive 
value for response to treatment with prucalopride in patients with chronic 
constipation.
GASTROINTESTINAL DISORDERS – Cost Studies
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OBJECTIVES: To evaluate the direct costs related to recurrence of inguinal hernia 
repair, in patients who underwent the surgery with PHS versus Polypropylene mesh, 
under the Brazilian private payer perspective. METHODS: A decision model was 
developed to assess the costs and resource usage for the recurrence of inguinal hernia 
repair with the PHS versus Polypropylene mesh under the private payer perspective, 
